Loading data...
Loading data...
Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | ADCT ADC Therapeutics SA Common | ABBV AbbVie |
|---|---|---|
| Price | $1.11 +3.7% | $261.77 +1.8% |
| StockIQ Score | 45D+ Moderate Risk: Medium | 53C- Moderate Risk: Medium |
| Technical | 40D | 61C+ |
| Fundamental | 46D+ | 56C |
| Growth | 59C | 34F |
| Fair Value | 50C- | 33F |
| News | 20F | 98A+ |
| Quality | 47D+ | 47D+ |
| Risk | 46D+ | 48D+ |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
ABBV scores higher on investor (53 vs 45), technical (61 vs 40) and fundamental metrics (56 vs 46). ADCT leads in growth (59 vs 34) and valuation (50 vs 33). Each stock is stronger in different areas, with ABBV excelling in overall stability measures and ADCT showing better growth and valuation potential.